Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 17/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338199 | 1.00 | GRIA4 (0.67) | GRIA4GRIA2GRIA1GRIA3CA1 | |
| SCHEMBL3799849 | 1.00 | GRIA4 (0.67) | GRIA4GRIA2GRIA1GRIA3CA1 | |
| SCHEMBL6565117 | 0.91 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.86 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877671 | 0.86 | GRIA4 (0.73) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL13255761 | 0.86 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878987 | 0.84 | GRIA4 (0.90) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL7051992 | 0.84 | GRIA4 (0.49) | GRIA4GRIA2GRIA1GRIA3CA1 | |
| SCHEMBL6555614 | 0.83 | GRIA4 (0.67) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877864 | 0.83 | GRIA4 (0.91) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-07 | — | — | US | disclosed |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 11/4885GRIA2 9/4885GRIA1 6/4885 |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 12/4885GRIA2 4/4885GRIA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.